Authors
Latest:
Dr. Andikyan on the Rationale of Using HIPEC in Ovarian CancerVaagn Andikyan, MD, discusses the utilization of hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer.
Latest:
Early Efficacy Data With RP2 in Advanced Solid TumorsFrancesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.
Latest:
Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric CancerShared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Latest:
Next Steps With Pembrolizumab/Lenvatinib in Endometrial CancerChristian Marth, MD, PhD, discusses next steps with pembrolizumab and lenvatinib for use in the advanced or recurrent endometrial cancer treatment paradigm.
Latest:
Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic MalignanciesAjeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.
Latest:
Rapid Readout: Post Hoc Analysis of Responses to Ponatinib in patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC TrialDr Smith reviews post-hoc data from the OPTIC trial which assessed the safety and efficacy of ponatinib in patients with CP-CML whose disease was resistant to 2 or more TKIs or who have a T3151 mutation.
Latest:
Clinical Benefits With Neratinib in HER2+ Early Breast CancerVijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.
Latest:
Dr. Sanjeevaiah on the Benefit of Immunotherapy Agents in Gastric CancersAravind R. Sanjeevaiah, MD, discusses the benefit of immunotherapy agents in the treatment of patients with gastric cancers.
Latest:
Mayo Clinic Physicians Seek to Address Bias in Medical EducationThe clinical learning environment for medical trainees is the foundation of medical training programs.
Latest:
ESMO 2021 Updates in Gastric Cancer and Colorectal CancerSam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.
Latest:
Dr Sun on the Association of Duration of Immunotherapy and OS in NSCLCLova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.
Latest:
Dr. Puertas‐Martinez on Carfilzomib and Dexamethasone plus Cyclophosphamide in Multiple MyelomaBorja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Guerra on a Culturally Tailored Approach to Prostate Cancer Screening AwarenessCarmen Guerra MD, MSCE, examines how a culturally sensitive could help raise prostate cancer screening awareness.
Latest:
Dr. Matthews on the Efficacy of CPX-351 Vs Venetoclax/Azacitidine in AMLAndrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.
Latest:
Raising the Bar for KRAS G12C+ Colorectal Cancer TreatmentWith 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.
Latest:
Dr. Gandhi on Key Interim Results From the SGN35-027 Trial in Hodgkin LymphomaMitul Gandhi, MD, discusses key findings from part C of the phase 2 SGN35-027 trial in Hodgkin lymphoma.
Latest:
VOD: Ensuring Best OutcomesExperts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.
Latest:
Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL ModelsGaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.
Latest:
Treatment Paradigms Are Shifting for Locally Advanced HPV-Positive Head and Neck CancersA personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.
Latest:
Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCLPeter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.
Latest:
Dr. Woloszynska on the Role of Community Outreach in Addressing Disparities in Prostate CancerAnna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.
Latest:
Dr Mohindra on Updates in SCLC ManagementNisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.
Latest:
Megahed on the Effects of NGS on First-Line Treatment Decisions in NSCLCAhmed Megahed, MBBCh, discusses the rationale for investigating the effects of next-generation sequencing on first-line treatment decisions for patients with stage IV non–small cell lung cancer.
Latest:
Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial CancersMegan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.
Latest:
Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple MyelomaAriel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.
Latest:
Dr. Hunter on the Role of 18F-FES-PET Imaging in Triple-Positive Breast CancerNatasha B Hunter, MD, discusses the utility of 18F-Fluoroestradiol PET imaging for patients with estrogen receptor–positive and HER2-positive breast cancer.
Latest:
Dr Ecker on the Investigation of the Microbiome in Pancreatic CancerBrett L. Ecker, MD, discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.
Latest:
Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLLLindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.
Latest:
Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid TumorsBob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.
Latest:
Ongoing Studies in Genomic Testing for Breast CancerClosing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.
